Orchestra BioMed Holdings, Inc. (OBIO) Stock Price, Financials & Summary

Price chart

Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18

Key dataSep 18, 2026

Open$5.86

From 52W high−0.65%

Volume1.06M

Market cap$365.44M

P/E (TTM)—

P/S (TTM)11.4x

Div yield—

Key dataSep 18, 2026

Open

$5.86

From 52W high

−0.65%

Volume

1.06M

Market cap

$365.44M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−5.9x

P/E (TTM)

—

RSI (14)

61.7

MomentumView details →

1D Return

+5.19%

YTD Return

+39.52%

SummaryUpdated Jun 1, 2026

Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) is a biomedical innovation company founded in 2020 and based in New Hope, Pennsylvania. The company went public on August 4, 2020, and operates as a development-stage biotechnology firm focused on creating medical devices and therapies for cardiovascular and other critical health conditions. Orchestra BioMed has established strategic partnerships with major medical device companies including Medtronic and Terumo Corporation to advance its product pipeline through clinical development and eventual commercialization.

Ask drillr about Orchestra BioMed Holdings, Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−5.9x

EV/Sales

10.5x

P/S (TTM)

11.4x

P/B (TTM)

12.4x

ProfitabilityView details →

Gross Margin

99.32%

Net Margin

−184.60%

EBITDA Margin

−178.56%

ROE (TTM)

−200.64%

ROA (TTM)

−51.02%

Asset Turnover

0.30x

GrowthView details →

Revenue YoY

+986.14%

EPS YoY

+45.60%

FCF YoY

+1.01%

Revenue CAGR 3Y

+111.62%

EPS CAGR 3Y

+33.13%

EBITDA YoY

+19.37%

MomentumView details →

1D Return

+5.19%

YTD Return

+39.52%

1Y Return

+137.30%

RSI (14)

61.7

vs 50D SMA

+23.89%

vs 200D SMA

+34.03%

Capital & dividendView details →

Debt/Equity

2.41x

Current Ratio

8.26x

Quick Ratio

8.24x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.38

EPS Surprise

3.06%

Beats (12Q)

8/12

Next Q EPS Est

−$0.40

Avg Surprise (4Q)

47.84%

Rev Surprise

−36.10%

Financials snapshotView financials →

Revenue (TTM)

31.98M

Net Income (TTM)

−59.03M

Op. CF (TTM)

−58.32M

Next earningsNov 9, 2026 →

Latest newsMore news →

Haemonetics Corporation acquired Vivasure Medical Limited, with Orchestra BioMed receiving a $6.1 million milestone payment on September 14, 2026 as part of the deal.5d ago

Similar companies

DiaMedica Therapeutics Inc.DMAC Rezolute, Inc.RZLT BioAge Labs, Inc.BIOA Rocket Pharmaceuticals, Inc.RCKT Ocugen, Inc.OCGN Fennec Pharmaceuticals Inc.FENC Find similar companies →

Latest newsMore news →

Orchestra BioMed announced that its investigational AVIM Therapy will be featured in two sessions at HRX Live 2026, the Heart Rhythm Society's annual meeting in Atlanta, Georgia on September 18-20, 2026.4d ago Haemonetics Corporation acquired Vivasure Medical Limited, with Orchestra BioMed receiving a $6.1 million milestone payment on September 14, 2026 as part of the deal.5d ago